Treanda (bendamustine, SDX-105)
Updated: Nov 14, 2009
| Brand Name: | Treanda |
| Generic Name: | bendamustine |
| Code Name: | SDX-105 |
| Company: | Cephalon Oncology |
| FDA Clinical Phase: | 1/2 |
Description:
Treanda (news articles) is a drug that is used to treat chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin’s lymphoma (NHL) . It is also being studied in the treatment of other types of cancer. Treanda is a type of purine analog/alkylator hybrid drug, which may damage the DNA in cancer cells and kill them.
Clinical Trials:
For a list of clinical trials studying Treanada for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official website for Treanda: http://www.treanda.com/
Source: NCI Cancer Glossary, Treanda, http://www.cancer.gov/dictionary/?searchTxt=treanda (as of November 14, 2009)
Related Articles:
- FDA Approves Cephalon’s Treanda For Second Cancer Indication
- Treanda In Combination With Steroids May Be Effective In Relapsed And Refractory Multiple Myeloma Patients
- Treanda Shows Promising Activity In Relapsed/Refractory Multiple Myeloma Patients (ASH 2010 Meeting)
- ASH 2011 Multiple Myeloma Update – Day Three Morning: New Therapies
- Beacon NewsFlashes – April 12, 2010
Leave a comment